BioRad Laboratories (BIO.B)
(Delayed Data from NYSE)
$284.88 USD
0.00 (0.00%)
Updated Sep 19, 2025 01:51 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIO.B 284.88 0.00(0.00%)
Will BIO.B be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIO.B based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BIO.B
BIO.B Crossed Above 20 Day Moving Average on September 19
Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
Bruker: Former Academia Customer Strength, Now Incredible Weakness
Bio-Rad Laboratories: Macroeconomic Uncertainty And A Limited Growth Potential Give Pause
Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition